Patents by Inventor Gregory M. Acland
Gregory M. Acland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170014529Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.Type: ApplicationFiled: July 27, 2016Publication date: January 19, 2017Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William H. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
-
Publication number: 20160263246Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.Type: ApplicationFiled: May 4, 2016Publication date: September 15, 2016Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
-
Patent number: 9433688Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.Type: GrantFiled: June 20, 2014Date of Patent: September 6, 2016Assignees: The Trustees of the University of Pennsylvania, University of Florida Research Foundation, Incorporated, Cornell Research Foundation, Inc.Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
-
Publication number: 20140377224Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.Type: ApplicationFiled: June 20, 2014Publication date: December 25, 2014Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, CORNELL RESEARCH FOUNDATION, INC.Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
-
Publication number: 20120225930Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.Type: ApplicationFiled: February 28, 2012Publication date: September 6, 2012Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
-
Patent number: 8206911Abstract: Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.Type: GrantFiled: March 1, 2010Date of Patent: June 26, 2012Assignee: Cornell Research Foundation, Inc.Inventors: Gustavo Aguirre, Gregory M. Acland, Barbara Zangerl, Orly Goldstein, Susan Pearce-Kelling, Jeanette S. Felix, Duska J. Sidjanin
-
Patent number: 8147823Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.Type: GrantFiled: July 8, 2010Date of Patent: April 3, 2012Assignees: The Trustees of the University of Pennsylvania, University of Florida Research Foundation, Incorporated, Cornell Research Foundation Inc.Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
-
Patent number: 8119343Abstract: Provided are methods for identifying dogs as likely to be genetically normal, carriers of, or affected with Oculo-skeletal dysplasia (OSD) by determining the presence or absence of a drd2 COL9A2 mutation and/or a drd1 COL9A3 mutation. Also provided is a method for selective breeding of dogs and kits useful for carrying out the methods of the invention.Type: GrantFiled: August 27, 2008Date of Patent: February 21, 2012Assignee: Cornell UniversityInventors: Gregory M. Acland, Orly Goldstein, Anna V. Kukekova, Jennifer Lynn Johnson
-
Publication number: 20100323349Abstract: Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.Type: ApplicationFiled: March 1, 2010Publication date: December 23, 2010Inventors: Gustavo Aguirre, Gregory M. Acland, Barbara Zangerl, Orly Goldstein, Susan Pearce-Kelling, Jeanette S. Felix, Duska J. Sidjanin
-
Publication number: 20100272688Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.Type: ApplicationFiled: July 8, 2010Publication date: October 28, 2010Applicants: The Trustees of the University of Pennsylvania, University of Florida Research Foundation, Incorporated, Cornell Research Fountaintion, Inc.Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
-
Patent number: 7811761Abstract: Provided is a method for identifying dogs as likely to be genetically normal, carriers of, or affected with progressive rod-cone degeneration comprising analyzing nucleic acids from a dog and determining the presence or absence of one or more prcd polymorphisms in the nucleic acids. Representative prcd polymorphisms characteristic of a prcd haplotype are also provided.Type: GrantFiled: December 13, 2006Date of Patent: October 12, 2010Assignee: Cornell Research Foundation, Inc.Inventors: Gregory M. Acland, Gustavo D. Aguirre, Orly Goldstein, Barbara Zangerl, Susan Pearce-Kelling, Duska J. Sidjanin, Jeanette S. Felix
-
Patent number: 7723507Abstract: The invention relates to a method for identifying dogs which are genetically normal, heterozygous for, or homozygous for the mutation primarily responsible for Collie eye anomaly (CEA). The method comprises the steps of obtaining a biological sample from a dog and testing DNA in the biological sample for the presence or absence of a 7.8 kilobase deletion within chromosome 37 in which the CEA mutation is located. No deletion is indicative of a normal dog. A deletion on one allele of chromosome 37 is indicative of a dog that is heterozygous for the CEA mutation. A deletion in both alleles of chromosome 37 are indicative of a dog that is homozygous for the CEA mutation. Also provided is a kit for identifying a dog as normal, heterozygous for, or homozygous for the CEA mutation.Type: GrantFiled: September 22, 2008Date of Patent: May 25, 2010Assignee: Cornell Research Foundation, Inc.Inventors: Gregory M. Acland, Anna V. Kukekova, Gustavo D. Aguirre, Elaine Ostrander, Dayna Akey, Orly Goldstein
-
Patent number: 7671187Abstract: Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.Type: GrantFiled: November 13, 2007Date of Patent: March 2, 2010Assignee: Cornell Research Foundation, Inc.Inventors: Gustavo Aguirre, Gregory M. Acland, Barbara Zangerl, Orly Goldstein, Susan Pearce-Kelling, Jeanette S. Felix, Duska J. Sidjanin
-
Publication number: 20090176225Abstract: The invention relates to a method for identifying dogs which are genetically normal, heterozygous for, or homozygous for the mutation primarily responsible for Collie eye anomaly (CEA). The method comprises the steps of obtaining a biological sample from a dog and testing DNA in the biological sample for the presence or absence of a 7.8 kilobase deletion within chromosome 37 in which the CEA mutation is located. No deletion is indicative of a normal dog. A deletion on one allele of chromosome 37 is indicative of a dog that is heterozygous for the CEA mutation. A deletion in both alleles of chromosome 37 are indicative of a dog that is homozygous for the CEA mutation. Also provided is a kit for identifying a dog as normal, heterozygous for, or homozygous for the CEA mutation.Type: ApplicationFiled: September 22, 2008Publication date: July 9, 2009Inventors: Gregory M. Acland, Anna V. Kukekova, Gustavo D. Aguirre, Elaine Ostrander, Dayna Akey, Orly Goldstein
-
Publication number: 20090111976Abstract: Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.Type: ApplicationFiled: November 13, 2007Publication date: April 30, 2009Inventors: Gustavo Aguirre, Gregory M. Acland, Barbara Zangerl, Orly Goldstein, Susan Pearce-Kelling, Jeanette S. Felix, Duska J. Sidjanin
-
Publication number: 20090074723Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.Type: ApplicationFiled: October 18, 2008Publication date: March 19, 2009Applicants: The Trustees of the University of Pennsylvania, The University of Florida Research Foundation, Inc., Cornell Research Foundation, Inc.Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
-
Publication number: 20090061448Abstract: Provided are methods for identifying dogs as likely to be genetically normal, carriers of, or affected with Oculo-skeletal dysplasia (OSD) by determining the presence or absence of a drd2 COL9A2 mutation and/or a drd1 COL9A3 mutation. Also provided is a method for selective breeding of dogs and kits useful for carrying out the methods of the invention.Type: ApplicationFiled: August 27, 2008Publication date: March 5, 2009Applicant: Cornell Research Foundation, Inc.Inventors: Gregory M. Acland, Orly Goldstein, Anna V. Kukekova, Jennifer Lynn Johnson
-
Patent number: 7462455Abstract: The invention relates to a method for identifying dogs which are genetically normal, heterozygous for, or homozygous for the mutation primarily responsible for Collie eye anomaly (CEA). The method comprises the steps of obtaining a biological sample from a dog and testing DNA in the biological sample for the presence or absence of a 7.8 kilobase deletion within chromosome 37 in which the CEA mutation is located. No deletion is indicative of a normal dog. A deletion on one allele of chromosome 37 is indicative of a dog that is heterozygous for the CEA mutation. A deletion in both alleles of chromosome 37 are indicative of a dog that is homozygous for the CEA mutation. Also provided is a kit for identifying a dog as normal, heterozygous for, or homozygous for the CEA mutation.Type: GrantFiled: October 20, 2005Date of Patent: December 9, 2008Assignee: Cornell Research Foundation, Inc.Inventors: Gregory M. Acland, Anna V. Kukekova, Gustavo D. Aguirre, Elaine Ostrander, Dayna Akey, Orly Goldstein
-
Patent number: 7312037Abstract: Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.Type: GrantFiled: June 21, 2005Date of Patent: December 25, 2007Assignee: Cornell Research Foundation, Inc.Inventors: Gustavo Aguirre, Gregory M. Acland, Barbara Zangerl, Orly Goldstein, Susan Pearce-Kelling, Jeanette S. Felix, Duska J. Sidjanin
-
Publication number: 20040022766Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.Type: ApplicationFiled: November 20, 2002Publication date: February 5, 2004Inventors: Gregory M. Acland, Gustayo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire